...
search icon
irwd-img

Ironwood Pharmaceuticals Inc, Common Stock

IRWD

NSQ

$3.71

-$0.06

(-1.59%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$603.31M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.00M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.47
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.06 L
$15.7 H
$3.71

About Ironwood Pharmaceuticals Inc, Common Stock

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIRWDSectorS&P500
1-Week Return1.37%2.78%2.05%
1-Month Return-19.52%3.42%1.43%
3-Month Return-6.78%-3.57%5.3%
6-Month Return-44.21%-3.86%12.75%
1-Year Return-72.13%3.89%25.72%
3-Year Return-66.88%11.66%38.66%
5-Year Return-70.01%40.62%85.64%
10-Year Return-73.39%102.05%197.6%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue428.41M389.52M413.75M410.60M442.74M[{"date":"2019-12-31","value":96.77,"profit":true},{"date":"2020-12-31","value":87.98,"profit":true},{"date":"2021-12-31","value":93.45,"profit":true},{"date":"2022-12-31","value":92.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue23.88M3.14M1.52M1.42M104.78M[{"date":"2019-12-31","value":22.78,"profit":true},{"date":"2020-12-31","value":2.99,"profit":true},{"date":"2021-12-31","value":1.45,"profit":true},{"date":"2022-12-31","value":1.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit404.54M386.39M412.23M409.18M337.95M[{"date":"2019-12-31","value":98.13,"profit":true},{"date":"2020-12-31","value":93.73,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.26,"profit":true},{"date":"2023-12-31","value":81.98,"profit":true}]
Gross Margin94.43%99.19%99.63%99.65%76.33%[{"date":"2019-12-31","value":94.75,"profit":true},{"date":"2020-12-31","value":99.54,"profit":true},{"date":"2021-12-31","value":99.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.6,"profit":true}]
Operating Expenses287.49M228.06M181.54M160.26M1.28B[{"date":"2019-12-31","value":22.4,"profit":true},{"date":"2020-12-31","value":17.77,"profit":true},{"date":"2021-12-31","value":14.15,"profit":true},{"date":"2022-12-31","value":12.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income120.12M142.94M232.26M250.34M(945.43M)[{"date":"2019-12-31","value":47.98,"profit":true},{"date":"2020-12-31","value":57.1,"profit":true},{"date":"2021-12-31","value":92.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-377.66,"profit":false}]
Total Non-Operating Income/Expense(94.92M)(62.05M)(62.03M)3.99M5.85M[{"date":"2019-12-31","value":-1622.01,"profit":false},{"date":"2020-12-31","value":-1060.37,"profit":false},{"date":"2021-12-31","value":-1059.91,"profit":false},{"date":"2022-12-31","value":68.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income58.94M108.86M200.66M252.42M(948.07M)[{"date":"2019-12-31","value":23.35,"profit":true},{"date":"2020-12-31","value":43.13,"profit":true},{"date":"2021-12-31","value":79.49,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-375.59,"profit":false}]
Income Taxes74.26M2.69M(327.79M)77.36M83.49M[{"date":"2019-12-31","value":88.94,"profit":true},{"date":"2020-12-31","value":3.22,"profit":true},{"date":"2021-12-31","value":-392.61,"profit":false},{"date":"2022-12-31","value":92.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(15.31M)106.18M528.45M175.06M(1.03B)[{"date":"2019-12-31","value":-2.9,"profit":false},{"date":"2020-12-31","value":20.09,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":33.13,"profit":true},{"date":"2023-12-31","value":-195.21,"profit":false}]
Income From Continuous Operations58.94M106.18M528.45M175.06M(980.95M)[{"date":"2019-12-31","value":11.15,"profit":true},{"date":"2020-12-31","value":20.09,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":33.13,"profit":true},{"date":"2023-12-31","value":-185.63,"profit":false}]
Income From Discontinued Operations(37.44M)----[{"date":"2019-12-31","value":-3743800000,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(15.31M)106.18M528.45M175.06M(1.00B)[{"date":"2019-12-31","value":-2.9,"profit":false},{"date":"2020-12-31","value":20.09,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":33.13,"profit":true},{"date":"2023-12-31","value":-189.66,"profit":false}]
EPS (Diluted)0.540.791.180.970.64[{"date":"2019-12-31","value":45.76,"profit":true},{"date":"2020-12-31","value":66.95,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.2,"profit":true},{"date":"2023-12-31","value":54.24,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IRWD
Cash Ratio 1.79
Current Ratio 3.62

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IRWD
ROA (LTM) 13.05%
ROE (LTM) -574.72%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IRWD
Debt Ratio Lower is generally better. Negative is bad. 1.80
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.80

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IRWD
Trailing PE NM
Forward PE 12.33
P/S (TTM) 1.57
P/B 2.59
Price/FCF 60
EV/R 2.96
EV/Ebitda 10.55
PEG NM

FAQs

What is Ironwood Pharmaceuticals Inc share price today?

Ironwood Pharmaceuticals Inc (IRWD) share price today is $3.71

Can Indians buy Ironwood Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Ironwood Pharmaceuticals Inc (IRWD) on Vested. To buy Ironwood Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IRWD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ironwood Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Ironwood Pharmaceuticals Inc (IRWD) via the Vested app. You can start investing in Ironwood Pharmaceuticals Inc (IRWD) with a minimum investment of $1.

How to invest in Ironwood Pharmaceuticals Inc shares from India?

You can invest in shares of Ironwood Pharmaceuticals Inc (IRWD) via Vested in three simple steps:

  • Click on Sign Up or Invest in IRWD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ironwood Pharmaceuticals Inc shares
What is Ironwood Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Ironwood Pharmaceuticals Inc (IRWD) is $15.7. The 52-week low price of Ironwood Pharmaceuticals Inc (IRWD) is $3.06.

What is Ironwood Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Ironwood Pharmaceuticals Inc (IRWD) is

What is Ironwood Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ironwood Pharmaceuticals Inc (IRWD) is 2.59

What is Ironwood Pharmaceuticals Inc dividend yield?

The dividend yield of Ironwood Pharmaceuticals Inc (IRWD) is 0.00%

What is the Market Cap of Ironwood Pharmaceuticals Inc?

The market capitalization of Ironwood Pharmaceuticals Inc (IRWD) is $603.31M

What is Ironwood Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Ironwood Pharmaceuticals Inc is IRWD

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top